top of page
Search


Beyond Cancer: CAR T Therapy Targets Autoimmunity, Infection, and More
Published on Spencer Knight via LinkedIn CAR T-cell therapy has revolutionized oncology, but its next frontier is outside of cancer...
Jun 17


Gene Therapy Pipeline Reaches Over 1,000 Trials for Rare Diseases
Published on Spencer Knight via LinkedIn There are more than 300 million people worldwide living with rare diseases, many of them with no...
Jun 17


Gene Therapy Restores Hearing in UK Toddler Born Deaf
Published on Spencer Knight via LinkedIn Regeneron has announced a major milestone in pediatric gene therapy using its DB-OTO treatment....
Jun 17


Gene Therapy Restores Sight in Blind Children with Rare Eye Disorder
Published on Spencer Knight via LinkedIn A gene therapy trial at Moorfields Eye Hospital in London has given four children born with...
Jun 17


18 Years Cancer-Free: The Longest CAR-T Survivor Shows Solid Tumor Success Is Possible
Published on Spencer Knight via LinkedIn Between 2004 - 2009, 19 children with neuroblastoma joined a CAR-T clinical trial at Baylor...
Jun 17


Gene Editing Landscape: 187 Companies, 3 Focus Areas, and a $17B Market by 2028
Published on Spencer Knight via LinkedIn Spencer Knight shares a compelling visual breakdown of 187 gene editing companies across four...
Jun 17


Lyfgenia Gene Therapy Ends Pain for Sickle Cell Patient in Long Island Breakthrough
Published on Spencer Knight via LinkedIn 21-year-old Sebastien Beauzile spent his life in constant pain from sickle cell disease, unable...
Jun 17


From Hype to Hope: CGT Enters the Slope of Enlightenment
Published on Spencer Knight via LinkedIn CAR-T once promised a revolution, then came the cost, complexity, and clinical setbacks. Spencer...
Jun 17


Sana’s Cell Therapy Restores Insulin Without Immunosuppression: A Game Changer for Type 1 Diabetes
Published on Spencer Knight via LinkedIn Sana Biotechnology has announced successful first-in-human results using HIP-engineered islet...
Jun 17


Pushing the Limits: How XCell® ATF Hits 200M+ Cells/mL Across Modalities
Published on Repligen Poster, Bioprocessing Summit (July 2023) With biologics becoming more complex and global manufacturing capacity...
Jun 16


MSD Animal Health Boosts Animal Vaccine Yield with XCell ATF® Intensification
Published on Repligen White Paper (July 2022) Facing growing demand for veterinary vaccines, MSD Animal Health partnered with Repligen to...
Jun 16


10X Lentivirus Yield With TFDF Perfusion: Scaling CAR-T Manufacturing Without Scaling the Bioreactor
Published on Repligen Application Note (Sept 2024) Lentiviral vector production is a major bottleneck in CAR-T manufacturing, but...
Jun 16


TFDF Perfusion Boosts AAV and Lentiviral Vector Yields Up to 80-Fold
Published on Repligen Scientific Poster (Sept 2022) To meet growing demand in gene therapy, Repligen scientists applied tangential flow...
Jun 16


XCell ATF System: Scaling Upstream Bioprocessing with Perfusion Efficiency
Published on Repligen Brochure (Nov 2024) Repligen’s XCell ATF System brings upstream process intensification to life by enabling...
Jun 16


Sarawak Launches SSCTR: A Bold Leap in Biomedical Research
Published on The Borneo Post (June 14, 2025) Sarawak has officially launched the Sarawak Society for Cell and Gene Therapy...
Jun 14


Temple Study: CRISPR Removes HIV-Like Virus in Primate Models
Published on Temple University News (August 28, 2024) In a major preclinical breakthrough, researchers at Temple University and Excision...
Jun 13


Understanding Gene Delivery: A Practical Overview of Transfection Methods
Published on Lonza White Paper (CD-DS008) Choosing the right transfection method is key in gene therapy and biomedical research. This...
Jun 13


Automating Non-Viral Cell Therapy Manufacturing: Cocoon® Meets Nucleofector®
Published on Lonza White Paper (CT-SP008) Cell therapy manufacturing is often held back by viral vector limitations and labor-intensive...
Jun 13


How Large-Volume Electroporation Is Powering the Next Phase of Cell Therapy
Published on Lonza Overview (CT-SP019) Scaling cell therapy from benchtop to bedside requires technologies that are efficient, compliant,...
Jun 13


Expanding Gamma Delta T Cells: Two Scalable Methods Shaping Cell Therapy
Published on Lonza Poster Presentation (CT-SP020) Gamma delta (γδ) T cells are gaining momentum as a promising cell therapy platform due...
Jun 13
bottom of page
